 |
 |
US National Institute on Drug Abuse: Infofax - Ecstasy - 13547 MDMA, called "Adam," "ecstasy," or "XTC" on the street, is a synthetic, psychoactive (mind-altering) drug with amphetamine-like and hallucinogenic properties. Its chemical structure (3-4 methylenedioxymethamphetamine) is similar to two other synthetic drugs, MDA and methamphetamine, which are known to cause brain damage. Health Hazards Beliefs about MDMA are reminiscent of the claims made about LSD in the 1950s and 1960s, which proved to be untrue. According to its proponents, MDMA can make people trust each other and can break down barriers between therapists and patients, lovers, and family members. Many of the risks users face with MDMA use are similar to those found with the use of amphetamines and cocaine. They are: Psychological difficulties, including confusion, depression, sleep problems, drug craving, severe anxiety, and paranoia - during and sometimes weeks after taking MDMA (even psychotic episodes have been reported). Physical symptoms such as muscle tension, involuntary teeth clenching, nausea, blurred vision, rapid eye movement, faintness, and chills or sweating. Increases in heart rate and blood pressure, a special risk for people with circulatory or heart disease. Recent research findings also link MDMA use to long-term damage to those parts of the brain critical to thought and memory. It is thought that the drug causes damage to the neurons that use the chemical serotonin to communicate with other neurons. In monkeys, exposure to MDMA for 4 days caused brain damage that was evident 6 to 7 years later. This study provides further evidence that people who take MDMA may be risking permanent brain damage Also, there is evidence that people who develop a rash that looks like acne after using MDMA may be risking severe side effects, including liver damage, if they continue to use the drug. MDA, the parent drug of MDMA, is an amphetamine-like drug that has also been abused and is similar in chemical structure to MDMA. Research shows that MDA destroys serotonin-producing neurons in the brain, which play a direct role in regulating aggression, mood, sexual activity, sleep, and sensitivity to pain. It is probably this action on the serotonin system that gives MDA its purported properties of height-ened sexual experience, tranquillity, and conviviality. MDMA also is related in its structure and effects to methamphetamine, which has been shown to cause degeneration of neurons containing the neurotransmitter dopamine. Damage to these neurons is the underlying cause of the motor disturbances seen in Parkinson's disease. Symptoms of this disease begin with lack of coordination and tremors and can eventually result in a form of paralysis. Extent of Use - Community Epidemiology Work Group (CEWG) MDMA is used most often by young adults and adolescents at clubs, raves (large, all-night dance parties), and rock concerts. Its abuse is increasingly reported in the 20 metropolitan areas included in the CEWG. In Kings County, Washington, a recently completed survey of young men who have sex with men showed that MDMA was among the frequently used drugs (20 percent of the sample). In Boston, a 1996-97 survey of public schools in Boston found that about 14 percent of male and 7 percent of female 12th graders had used MDMA during their lifetime. Increased use of MDMA among youth was also reported in Seattle. Information about MDMA from other CEWG areas include the following: In Atlanta, MDMA is reported as a popular stimulant. In Chicago, its use is common in the rave and club scenes, especially in the North Side. In Miami, large-scale sales of drugs such as MDMA are occurring at raves. In New Jersey, it is available across the state, particularly in college towns. National Household Survey on Drug Abuse (NHSDA) Each year, NHSDA reports on the nature and extent of drug use among the American household population aged 12 and older. The 1998 survey found that an estimated 1.5 percent (3.4 million) of Americans at least 12 years old had used MDMA at least once during their lifetime. By age group, the heaviest use (5 percent or 1.4 million people) was reported for those between 18 and 25 years old. Monitoring the Future Study (MTF) In 1996, MTF began to collect data on MDMA use among students. Rates of use remained relatively stable from 1996 to 1999 for students in the 8th grade, while usage among 10th- and 12th-graders has increased. The number of 12th-graders that had used MDMA in their lifetime increased from 5.8 percent in 1998 to 8.0 percent in 1999. Use in the past year also increased from 3.6 percent in 1998 to 5.6 percent in 1999. In addition, 12th-graders use of MDMA in the past month also increased from 1.5 percent in 1998 to 2.5 percent in 1999. On the other hand, the largest change for 10th-graders occurred in past year use, which increased from 3.3 percent in 1998 to 4.4 percent in 1999. CEWG is a NIDA-sponsored network of researchers from 21 major U.S. metropolitan areas and selected foreign countries who meet semiannually to discuss the current epidemiology of drug abuse. CEWG's most recent reports are available on the CEWG web site. NHSDA is an annual survey conducted by the Substance Abuse and Mental Health Services administration. Copies of the latest survey are available from the National Clearinghouse for Alcohol and Drug Information at 1-800-729-6686. MTF is an annual survey on drug use and related attitudes of America's adolescents that began in 1975. In 1996, MTF began to collect data on MDMA use among students. The survey is conducted by the University of Michigan's Institute for Social Research and is funded by NIDA. Copies of the latest survey are available from the National Clearinghouse for Alcohol and Drug Information at 1-800-729-6686. US National Institute on Drug Abuse Call toll-free: 1-888-NIH-NIDA (1-888-644-6432) Deaf Callers: 1-888-TTY-NIDA (1-888-889-6432) US NIDA's Home Page: http://www.drugabuse.gov/ Send comments and questions to: US NIDA Infofax, P.O. Box 30652, Bethesda, MD. 20824-0652. For additional information about NIDA send e-mail to: [log in to unmask] This material may be used or reproduced without permission from NIDA. Citation of the source is appreciated. This page has been accessed 217138 times since 11/5/99. This page last updated Monday, January 22, 2001. http://www.nida.nih.gov/Infofax/ecstasy.html janet paterson, an akinetic rigid subtype parkie 53 now / 44 dx cd / 43 onset cd / 41 dx pd / 37 onset pd TEL: 613 256 8340 SMAIL: PO Box 171 Almonte Ontario K0A 1A0 Canada EMAIL: [log in to unmask] URL: http://www.geocities.com/janet313/